Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
PHILADELPHIA, Aug. 31, 2016 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments, announced today that members of company management or key investigators will present at the following major investor and scientific/medical conferences in September:
Citibank’s 11th Annual Biotech Conference, at the Mandarin Oriental Hotel, Boston
- Jeffrey D. Marrazzo, chief executive officer, will participate in a panel discussion – Gene Therapy: A New Era – on Wednesday, Sept. 7, at 1 p.m. (EDT)
- Webcast of the presentation will be available on www.Sparktx.com/investors
Baird 2016 Global Healthcare Conference, at the New York Palace Hotel, New York City
- Stephen Webster, chief financial officer, will present on Wednesday, Sept. 7, at 4:55 p.m. (EDT)
16th Congress of the European Retina, Macula and Vitreous Society (EURETINA), at the Bella Center, Copenhagen, Denmark
- Dr. Bart Leroy, director of the Ophthalmic Genetics and Retinal Degenerations clinics in the Division of Ophthalmology and Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia, will give a presentation entitled “Phase 3 study of voretigene neparvovec in subjects with RPE65-mediated inherited retinal dystrophy” on Friday, Sept. 9, at 5:24 p.m. CEST
Company representatives also will attend the following conferences for one-on-one meetings:
- Goldman Sachs 6th Annual Biotech Symposium, at Goldman Sachs’ Offices, London, on Friday, Sept. 9
- Bank of America / Merrill Lynch (BAML) Global HC Conference 2016, at the BOA/ML Financial Centre, London, on Wednesday, Sept. 14
About Spark Therapeutics
Spark Therapeutics, a fully integrated gene therapy company, is seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark Therapeutics’ validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal diseases, liver-associated diseases, such as hemophilia, and neurodegenerative diseases. Spark Therapeutics’ validated platform has successfully delivered gene therapies with proof-of-concept data in the eye and liver. Spark Therapeutics’ most advanced product candidate, voretigene neparvovec (formerly referred to as SPK-RPE65), which has received both breakthrough therapy and orphan product designations, reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of a rare blinding condition. Spark Therapeutics’ hemophilia franchise has two lead assets: SPK-9001 in a Phase 1/2 trial for hemophilia B and SPK-8011, a preclinical candidate for hemophilia A. To learn more, please visit www.sparktx.com.
Spark Therapeutics Corporate Contacts Stephen W. Webster Chief Financial Officer Daniel Faga Chief Business Officer (855) SPARKTX (1-855-772-7589) Media Contact: Dan Quinn Ten Bridge Communications (781) 475-7974 [email protected]
